Merck Animal Health

These websites are intended for US or Canada residents only.

MSD Animal Health is a division of Merck & Co., Inc., Kenilworth, N.J., USA. This link will take you to a website intended for those living outside the United States and Canada.

News Archive

24 May 2016

Merck Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On Solution for Cats and Dogs

                                                    Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks

MADISON, N.J., May 24, 2016 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced that, following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Medicine Agency has granted a marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) Spot-On Solution for both cats and dogs, a Spot-On treatment for fleas and ticks effective for 12 weeks following a single dose.

BRAVECTO Spot-On, a systemic insecticide and acaricide, is indicated for the treatment of tick and flea infestations on cats and dogs and provides immediate and persistent flea and tick killing activity for 12 weeks. BRAVECTO Spot-On is applied topically using the new “Twist’n’Use”™ pipette design for ease of application. Detailed conditions of the product will be described in the summary of product characteristics (SPC) which will be published in the European public assessment report (EPAR).

“Approval of BRAVECTO Spot-On builds on the strong foundation and body of scientific evidence that we have established with our chewable tablet for dogs, the oral flea and tick product available today,” said KJ Varma, senior vice president, research & development, Merck Animal Health. “BRAVECTO Spot-On now provides veterinarians and cat owners another tool in the fight against parasites and gives veterinarians and dog owners a choice in how to administer flea and tick protection that works quickly and lasts up to twelve weeks.”

In 2014, BRAVECTO was launched as a chewable tablet for dogs. More than 13 million doses of the BRAVECTO chew have been dispensed in 60 countries since its introduction.

Fleas and ticks must attach to the treated animal and commence feeding in order to be exposed to the active substance. The most common side effects of BRAVECTO Spot-On in dogs are mild and transient skin reactions such as erythema or alopecia at the application site and, in cats, pruritus at the application site. The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). The most common side effects of BRAVECTO chewable tablet administration to dogs are mild and transient gastrointestinal effects.

BRAVECTO Spot-On will be available in countries throughout Europe in the coming months. Veterinarians interested in learning more about BRAVECTO Spot-On should contact their MSD Animal Health representative.

About Merck Animal Health
For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA   
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (